Sixty-seven oncology physician group practices in 37 states will participate in the Enhanced Oncology Model, a voluntary five-year payment model that will begin July 1 for beneficiaries who receive systemic chemotherapy, the Centers for Medicare & Medicaid Services announced yesterday. The Center for Medicare and Medicaid Innovation model supports the administration’s moonshot goal to reduce cancer death rates by 50% over the next 25 years. Participating practices must provide 24/7 access to care, patient navigation and care planning; use certified electronic health record technology, evidence-based guidelines, electronic patient reported outcomes and data to improve quality; and must also screen for health-related social needs. The model will qualify as an alternative payment model under the Quality Payment Program’s Merit-based Incentive Payment System beginning in July. It offers two levels of downside risk, with the higher risk arrangement excluded from MIPS reporting requirements and payment adjustments as an Advanced APM. For more, see the model’s updated fact sheet.

Related News Articles

Headline
Aetna’s new “level of severity inpatient payment” policy is now set to take effect Jan. 1, 2026, the company recently announced, along with providing…
Blog
Public
The health care field has entered a period of disruption, from sweeping coverage changes to the rise of artificial intelligence (AI)-enabled tools. The…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
The AHA and a coalition of organizations yesterday urged House and Senate leaders to pass the Reforming and Enhancing Sustainable Updates to Laboratory Testing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…